Top 1% — Elite
Kizzmekia Corbett
Immunology · Viral Immunology
Boston, United States
50 H-Index
21,890 Citations
721 Total Impact
Overview
Kizzmekia Corbett is an immunology specialist with an H-index of 40 at Harvard T.H. Chan School of Public Health. Key scientist behind the Moderna COVID-19 mRNA vaccine spike protein design. Based in Boston, United States.
For Patients
- Pioneered the Designed spike protein immunogen for mRNA-1273 (Moderna COVID vaccine), a technique still used by doctors worldwide
- Research is cited 22K+ times by other doctors and scientists, indicating significant influence on medical research
- Currently at Harvard T.H. Chan School of Public Health in Boston, United States
Biography
Kizzmekia Corbett is an American immunologist and viral immunologist who was a key scientist behind the Moderna COVID-19 mRNA vaccine. She led the coronavirus team at the NIH Vaccine Research Center that designed the spike protein immunogen used in mRNA-1273, which has been administered to hundreds of millions worldwide.
Affiliations & Institutions
Research Impact
10 Publications
21,890 Total Citations
10K+ Citation Milestone
Publication Timeline
Published In
ScienceNew England Journal of MedicineNatureProceedings of the National Academy of SciencesbioRxiv (Cold Spring Harbor Laboratory)
Key Publications
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Areas of Expertise
Pioneering Techniques
Medical Specialties
Clinical Knowledge & Procedures
Legacy Timeline
The life and contributions of Kizzmekia Corbett
2014
Joined NIH Vaccine Research Center
Began research on coronavirus vaccines at the VRC
2020
Designed spike protein immunogen for Moderna vaccine
Led design of the antigen used in the mRNA-1273 COVID-19 vaccine
2021
Moderna mRNA-1273 received full FDA approval
Vaccine received full approval after demonstrating high efficacy
2022
Appointed to Harvard
Became assistant professor at Harvard T.H. Chan School of Public Health
Media Archive